KFDA nods Amosartan as first-line antihypertensive drug

Published: 2010-07-12 06:57:00

Updated: 2010-07-12 06:57:00

The Korea Food and Drug Administration approved the homegrown anti-hypertension combination drug “Amosartan” as a first-line drug in patients with more than moderate hypertension (systolic blood pressure; more than 160 mmHg, diastolic blood pressure; more than 100 mmHg), Hanmi Pharm said on July ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK